Journal article
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
Abstract
We conducted a randomized, controlled trial comparing thalidomide-prednisone as maintenance therapy with observation in 332 patients who had undergone autologous stem cell transplantation with melphalan 200 mg/m2. The primary end point was overall survival (OS); secondary end points were myeloma-specific progression-free survival,progression-free survival, incidence of venous thromboembolism, and health-related quality of life (HRQoL). With a …
Authors
Stewart AK; Trudel S; Bahlis NJ; White D; Sabry W; Belch A; Reiman T; Roy J; Shustik C; Kovacs MJ
Journal
Blood, Vol. 121, No. 9, pp. 1517–1523
Publisher
American Society of Hematology
Publication Date
February 28, 2013
DOI
10.1182/blood-2012-09-451872
ISSN
0006-4971